Management of motor and non-motor symptoms in Parkinson's disease. - Wikidata - awgldk - TriplyDB

Management of motor and non-motor symptoms in Parkinson's disease.

Management of motor and non-motor symptoms in Parkinson's disease.

http://www.wikidata.org/entity/Q38091653

about

Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease Nonpharmacological treatments for patients with Parkinson's disease.Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders.Parkinson's disease between internal medicine and neurology First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers Advances in non-dopaminergic treatments for Parkinson's disease Pramipexole extended-release: a review of its use in patients with Parkinson's disease.Nonmotor symptoms in sporadic versus familial forms of Parkinson's disease.Neuropathobiology of non-motor symptoms in Parkinson disease.Safinamide: A Review in Parkinson's Disease.An open-label pilot study with high-dose thiamine in Parkinson's disease.The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.Severely Affected by Parkinson Disease: The Patient's View and Implications for Palliative Care.

P2860

Q24187626-2380B79B-3F69-4621-AEF1-52AAD0B35567 Q30377906-E2A95505-3283-49BD-B58D-126937536DFC Q33800742-12D781FD-E7F3-4471-B67F-993D609C9354 Q36464243-23C51766-2413-4FEA-BFEE-67391E48FD39 Q37664213-6B0673FA-FC38-4811-B856-65C42789EB54 Q38218083-8DF75510-0D48-4D85-9F49-1F6121F205B8 Q38266818-0864D9CE-24B7-4CA5-9F8E-2BC7BE2AC714 Q38430846-E562368D-86E4-43EF-B1EC-449194AEE678 Q38481481-7778F77A-6944-496E-8292-4C420D3101B9 Q39097789-97D447DA-C85A-4383-9A43-0D6E70D65C28 Q40080011-D9C59AA9-5B05-4C56-AB7D-419F35F5F3D6 Q42094999-AC4A9F39-AA31-434F-9363-7D43E1D8F9FF Q47767613-0DD53BB1-C208-4231-A421-F51398ACD0E0

P2860

Management of motor and non-motor symptoms in Parkinson's disease.

http://www.wikidata.org/entity/Q38091653

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management of motor and non-motor symptoms in Parkinson's disease.

@en

type

label

Management of motor and non-motor symptoms in Parkinson's disease.

@en

prefLabel

Management of motor and non-motor symptoms in Parkinson's disease.

@en

P1433

Q38091653-BD697D93-BE67-4497-A7FC-26F988A1BE4D

P1476

Q38091653-BB2671FB-2DFE-4304-8BEB-CA2E0601BAB7

P2093

Q38091653-29F59B15-1D68-4EA8-936F-E2F2512A9941

P2860

Q38091653-027F66EA-F2E8-40FB-8C48-CDAEC431ECE7

Q38091653-02B2DF3F-5CFD-4B31-B44E-266A9BC1D5F2

Q38091653-047A7C50-53D2-4A8C-AE7A-94DCADEE7F6F

Q38091653-062279B9-B452-4819-85C9-505E413C7F6E

Q38091653-067C90CC-84B2-4BFE-A742-E272FA07A87B

Q38091653-0B11C3C8-9894-466D-96C5-44C87BBDCCEC

Q38091653-0C8F31F6-F62E-4E08-B8C2-D83302340F5C

Q38091653-0DB4B418-A8CA-43EA-BD31-B9BED601EAE2

Q38091653-114B8282-F211-4866-8AF1-14F2072A29E2

Q38091653-13054C41-59DF-4313-B216-11F282EBB1EE

P2888

Q38091653-3C9AB388-C7AF-433A-86B3-8B7AEE818D88

P304

Q38091653-4E3EA134-6153-4536-83DE-56E03B7E272B

P31

Q38091653-DDA323F1-EE01-4A09-B9BD-1DCE25227371

P356

Q38091653-D962DF54-44B0-43AF-A38A-7A7803518019

P433

Q38091653-5A18F61A-CF54-4095-BD34-218792B54C11

P478

Q38091653-3670C852-3924-43FB-BFA6-A4292A8B0F2D

P50

Q38091653-4BF7ECCB-528A-4989-833C-138603309E0B

P577

Q38091653-CA244CD8-FD9F-4C86-A027-B81AC2FFB827

P698

Q38091653-58911376-A560-493B-95BB-735CCFE10011

P356

S40263-013-0053-2

P1433

P1476

Management of motor and non-motor symptoms in Parkinson's disease.

@en

P2093

Fabienne Sprenger

http://www.w3.org/2001/XMLSchema#string

P2860

Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies

Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome

MAO inhibitors: risks, benefits, and lore

Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension

Frequency of bowel movements and the future risk of Parkinson's disease.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial.

EFNS guidelines on the diagnosis and management of orthostatic hypotension.

Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine.

P2888

s40263-013-0053-2

P304

259-272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40263-013-0053-2

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23515972

http://www.w3.org/2001/XMLSchema#string